ube2v2 Antibody

How does UBE2V2 function in cellular pathways?

UBE2V2 forms a catalytically active complex with UBE2N/Ubc13, which specifically catalyzes the formation of Lys63-linked poly-ubiquitin chains. This complex plays a crucial role in DNA damage response by forming foci in the nucleus following DNA damage. Mechanistically, the UBE2N/Ubc13-UBE2V2 complex interacts with SHPRH and HLTF ubiquitin ligases (E3s) to promote the poly-ubiquitination of PCNA, a key step in postreplication repair. Additionally, it works with the RNF8 E3 to poly-ubiquitinate Histone H2A and Histone H2AX near DNA double-stranded breaks, which is essential for recruiting DNA repair effector proteins.

What are the optimal conditions for UBE2V2 antibody storage and handling?

For optimal performance in research applications, UBE2V2 antibodies should typically be stored at -20°C for long-term preservation and 4°C for short-term use. When handling the antibody, it's crucial to avoid repeated freeze-thaw cycles as this can degrade the protein and reduce antibody efficacy. Most commercial UBE2V2 antibodies are stabilized in buffer solutions containing preservatives like sodium azide, which should be considered when designing experiments, especially those involving live cells or enzymatic assays where azide may interfere with results.

How is UBE2V2 involved in cancer progression mechanisms?

UBE2V2 has been identified as a potential oncogene in multiple cancer types. In lung adenocarcinoma (LUAD), elevated UBE2V2 expression correlates with poor prognosis based on both TCGA data analysis and immunohistochemistry studies. Mechanistically, UBE2V2 promotes cancer cell migration by regulating epithelial-mesenchymal transition (EMT)-related proteins. Knockdown experiments have demonstrated that reducing UBE2V2 expression induces G1 phase cell cycle arrest, increases apoptosis, and decreases proliferation in LUAD cells. These effects appear to be mediated through downregulation of PCNA and upregulation of P53 and ƳH2AX expression.

What are the optimal experimental conditions for immunohistochemistry (IHC) using UBE2V2 antibodies?

For effective immunohistochemistry with UBE2V2 antibodies, researchers should optimize several parameters. Tissue fixation is typically performed with 10% neutral buffered formalin for 24-48 hours, followed by paraffin embedding. Antigen retrieval methods (heat-induced epitope retrieval in citrate buffer pH 6.0 or EDTA buffer pH 9.0) should be optimized based on the specific antibody. Blocking with 3-5% BSA or serum for 30-60 minutes at room temperature helps reduce background staining. The primary UBE2V2 antibody concentration typically ranges from 1:100 to 1:500 dilution, optimized through titration. Overnight incubation at 4°C often yields optimal results, followed by appropriate secondary antibody and detection systems.

What techniques are most effective for validating UBE2V2 antibody specificity?

Rigorous validation of UBE2V2 antibody specificity is essential for reliable research results. Multiple complementary approaches should be employed, including:

• Western blotting with positive and negative control samples (tissues or cell lines with known UBE2V2 expression levels)

• siRNA or shRNA knockdown of UBE2V2 followed by Western blot or IHC to confirm decreased signal

• Peptide competition assays to verify binding specificity

• Comparison of staining patterns across multiple antibodies targeting different epitopes of UBE2V2

• Correlation of protein detection with mRNA expression data from PCR or RNA-seq

What signaling pathways should be examined when studying UBE2V2 function?

Gene Set Enrichment Analysis (GSEA) has identified several key signaling pathways positively correlated with UBE2V2 expression that should be examined when studying its function. These include DNA replication, cell cycle regulation, mismatch repair, ubiquitin-mediated proteolysis, and nucleotide excision repair pathways. Conversely, pathways showing negative correlation with UBE2V2 include arachidonic acid metabolism, allograft rejection, hematopoietic cell lineage, leukocyte transendothelial migration, and intestinal immune network for IgA production. When designing experiments to investigate UBE2V2 function, researchers should consider incorporating markers from these pathways to comprehensively understand the biological context.

How can UBE2V2 antibodies be used to study the UBE2N/Ubc13-UBE2V2 complex formation?

To study the complex formation between UBE2V2 and UBE2N/Ubc13, researchers can employ several advanced techniques:

• Co-immunoprecipitation (Co-IP) using UBE2V2 antibodies followed by Western blotting for UBE2N/Ubc13

• Proximity ligation assay (PLA) to visualize and quantify the interactions in situ

• Fluorescence resonance energy transfer (FRET) with fluorescently tagged proteins to monitor real-time complex formation

• Bimolecular fluorescence complementation (BiFC) to visualize the complex in living cells

• Chromatin immunoprecipitation (ChIP) to study the recruitment of the complex to DNA damage sites

When interpreting results, it's important to consider that complex formation may be dynamic and context-dependent, particularly following DNA damage induction.

What considerations are important when selecting UBE2V2 antibodies for different experimental applications?

When selecting UBE2V2 antibodies for specific applications, researchers should consider:

For all applications, monoclonal antibodies generally offer higher specificity but may recognize single epitopes that could be masked in certain conditions, while polyclonal antibodies provide robust detection across multiple epitopes but with potentially higher background.

How can UBE2V2 knockdown experiments be optimized to study its role in cancer progression?

For effective UBE2V2 knockdown studies investigating cancer progression mechanisms, researchers should implement:

• Multiple siRNA or shRNA constructs targeting different regions of UBE2V2 mRNA to rule out off-target effects

• CRISPR-Cas9 gene editing as a complementary approach for complete knockout studies

• Rescue experiments with ectopic expression of siRNA-resistant UBE2V2 to confirm phenotype specificity

• Dose-dependent knockdown to identify threshold levels required for phenotypic effects

• Time-course experiments to distinguish between immediate and secondary effects of UBE2V2 depletion

Phenotypic assessments should include EMT marker analysis (E-cadherin, N-cadherin, vimentin), cell cycle analysis (particularly G1 phase markers), apoptosis assays, proliferation measurements, and migration/invasion capabilities. Additionally, examining PCNA, P53, and ƳH2AX expression changes will help elucidate the molecular mechanisms underlying observed phenotypes.

What are common issues encountered with UBE2V2 antibodies in Western blotting and how can they be resolved?

Researchers frequently encounter several challenges when using UBE2V2 antibodies in Western blotting:

• Multiple bands: May indicate splice variants, post-translational modifications, or non-specific binding. Resolution approaches include using gradient gels for better separation, alternative antibodies targeting different epitopes, and confirming with knockout/knockdown controls.

• Weak signal: Often results from low protein abundance or inefficient transfer. Optimize by increasing protein loading (30-50 μg total protein), using enhanced chemiluminescence (ECL) detection, extending primary antibody incubation time (overnight at 4°C), and using PVDF membranes which generally bind more protein than nitrocellulose.

• High background: May be caused by insufficient blocking or washing. Improve by using 5% non-fat dry milk in TBST for blocking, extending washing steps (5 × 5 minutes), reducing antibody concentration, and using freshly prepared buffers.

• Inconsistent results: May stem from variable sample preparation. Standardize lysis conditions, include protease and phosphatase inhibitors, and maintain consistent protein quantification methods.

How can researchers differentiate between UBE2V2 and its homolog UBE2V1 in experimental systems?

• Antibody selection: Use antibodies raised against unique epitopes not conserved between UBE2V1 and UBE2V2. Verify specificity using recombinant proteins of both homologs in Western blots.

• PCR primer design: Design primers targeting non-conserved regions, ideally spanning exon-exon junctions to prevent genomic DNA amplification. Validate primer specificity using plasmids containing each homolog.

• RNA interference: When designing siRNA or shRNA for knockdown experiments, target unique sequences to avoid cross-silencing. Validate specificity by measuring both homologs' expression levels after knockdown.

• Functional assays: Since UBE2V1 and UBE2V2 have some distinct functions despite structural similarity, examining phenotypes specific to each protein can help confirm identity. For example, UBE2V2 has a more prominent role in DNA damage repair pathways.

• Co-immunoprecipitation: Analyze binding partners specific to each homolog, as their protein interaction networks differ.

What experimental approaches can resolve contradictory data about UBE2V2 function in different cancer types?

When faced with contradictory findings regarding UBE2V2 function across cancer types, researchers should implement these methodological approaches:

• Context-specific analysis: Perform parallel experiments in multiple cell lines representing different cancer types under identical conditions to directly compare UBE2V2 functions.

• Comprehensive profiling: Conduct RNA-seq and proteomics analyses to identify cancer-type-specific pathways and binding partners that might explain divergent functions.

• Domain-specific mutations: Create constructs with mutations in specific functional domains to determine which regions are responsible for context-dependent activities.

• In vivo validation: Utilize multiple animal models to validate in vitro findings and account for tumor microenvironment influences on UBE2V2 function.

• Patient sample correlation: Analyze patient-derived samples with detailed clinical annotation to correlate UBE2V2 expression with outcomes across cancer types and stages.

• Systematic review methodology: Implement meta-analysis techniques to compare study designs, methodologies, and controls when reviewing published literature with contradictory findings.